[Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--effects of protease inhibitors (PI) on MM2 ascites tumor growth, ascites accumulation and fibrinolysis].
The effects of protease inhibitors(PI), t-AMCHA, gabexate, aprotinin and heparin on the growth of mouse MM2 ascites tumor (MAT) and on several components of fibrinolysis were studied. The drugs were administered intraperitoneally one time daily for 12 days, one day after the tumor transplant. The volumes of ascites, total packed cell volume (TPCV) and fibrinolytic parameters (FDP, whole plasmin, plasminogen activator (PA)) were measured on the 8, 10 and 12th days of therapy. Fibrinolytic activity was assayed by the lysin sepharose affinity chromatography-radio caseinolytic method. Fibrinolytic activity in the ascites increased during the tumor growth. The ascites accumulation as well as levels of FDP, whole plasmin and PA in the drug treated group were significantly decreased when compared to the control group. In these drug-treated groups, MAT cells agglutinated in the abdominal cavity, but in contrast to this, no agglutination was observed in the control group. It was uncertain whether PI directly inhibited tumor growth. The fact that PI inhibited the ascites accumulation and also decreased fibrinolytic activity suggest the involvement of protease in the neoplastic process and indicates another therapeutic approach to malignant ascites tumors.
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001201:Ascites / Q000209:etiology*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis; D016670:Gabexate; D006146:Guanidines / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000150:complications / Q000378:metabolism*; D010538:Peritonitis / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology*; D014148:Tranexamic Acid / Q000494:pharmacology
D005338:Fibrin Fibrinogen Degradation Products; D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D014148:Tranexamic Acid; D006493:Heparin; D007611:Aprotinin; D010960:Plasminogen Activators; D005341:Fibrinolysin